141 related articles for article (PubMed ID: 12852438)
1. Glycosyl derivatives of dopamine and L-dopa as anti-Parkinson prodrugs: synthesis, pharmacological activity and in vitro stability studies.
Bonina F; Puglia C; Rimoli MG; Melisi D; Boatto G; Nieddu M; Calignano A; La Rana G; De Caprariis P
J Drug Target; 2003 Jan; 11(1):25-36. PubMed ID: 12852438
[TBL] [Abstract][Full Text] [Related]
2. Novel L-Dopa and dopamine prodrugs containing a 2-phenyl-imidazopyridine moiety.
Denora N; Laquintana V; Lopedota A; Serra M; Dazzi L; Biggio G; Pal D; Mitra AK; Latrofa A; Trapani G; Liso G
Pharm Res; 2007 Jul; 24(7):1309-24. PubMed ID: 17404814
[TBL] [Abstract][Full Text] [Related]
3. Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation.
Di Stefano A; Sozio P; Iannitelli A; Marianecci C; Santucci E; Carafa M
J Drug Target; 2006 Nov; 14(9):652-61. PubMed ID: 17090401
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of peptide derivatives of L-dopa as anti-parkinsonian agents.
Zhou T; Hider RC; Jenner P; Campbell B; Hobbs CJ; Rose S; Jairaj M; Tayarani-Binazir KA; Syme A
Bioorg Med Chem Lett; 2013 Oct; 23(19):5279-82. PubMed ID: 23973169
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and study of L-dopa-glutathione codrugs as new anti-Parkinson agents with free radical scavenging properties.
Pinnen F; Cacciatore I; Cornacchia C; Sozio P; Iannitelli A; Costa M; Pecci L; Nasuti C; Cantalamessa F; Di Stefano A
J Med Chem; 2007 May; 50(10):2506-15. PubMed ID: 17451233
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, in vitro and in vivo characterization of glycosyl derivatives of ibuprofen as novel prodrugs for brain drug delivery.
Chen Q; Gong T; Liu J; Wang X; Fu H; Zhang Z
J Drug Target; 2009 May; 17(4):318-28. PubMed ID: 19558357
[TBL] [Abstract][Full Text] [Related]
7. L-dopa- and dopamine-(R)-alpha-lipoic acid conjugates as multifunctional codrugs with antioxidant properties.
Di Stefano A; Sozio P; Cocco A; Iannitelli A; Santucci E; Costa M; Pecci L; Nasuti C; Cantalamessa F; Pinnen F
J Med Chem; 2006 Feb; 49(4):1486-93. PubMed ID: 16480285
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological studies of glycosyl dopamine derivatives as potential antiparkinsonian agents.
Fernández C; Nieto O; Rivas E; Montenegro G; Fontenla JA; Fernández-Mayoralas A
Carbohydr Res; 2000 Aug; 327(4):353-65. PubMed ID: 10990020
[TBL] [Abstract][Full Text] [Related]
9. Dimeric L-dopa derivatives as potential prodrugs.
Di Stefano A; Mosciatti B; Cingolani GM; Giorgioni G; Ricciutelli M; Cacciatore I; Sozio P; Claudi F
Bioorg Med Chem Lett; 2001 Apr; 11(8):1085-8. PubMed ID: 11327596
[TBL] [Abstract][Full Text] [Related]
10. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
Menzaghi F; Whelan KT; Risbrough VB; Rao TS; Lloyd GK
J Pharmacol Exp Ther; 1997 Jan; 280(1):393-401. PubMed ID: 8996220
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of L-(+)-3-(3-hydroxy-4-pivaloyloxybenzyl)-2,5-diketomorpholine as potential prodrug of L-dopa.
Cingolani GM; Di Stefano A; Mosciatti B; Napolitani F; Giorgioni G; Ricciutelli M; Claudi F
Bioorg Med Chem Lett; 2000 Jun; 10(12):1385-8. PubMed ID: 10890170
[TBL] [Abstract][Full Text] [Related]
12. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
Atlas D
CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations.
Di Stefano A; Carafa M; Sozio P; Pinnen F; Braghiroli D; Orlando G; Cannazza G; Ricciutelli M; Marianecci C; Santucci E
J Control Release; 2004 Sep; 99(2):293-300. PubMed ID: 15380638
[TBL] [Abstract][Full Text] [Related]
14. Multivariate statistical analysis of L-dopa esters as potential anti-parkinsonian prodrugs.
Van de Waterbeemd H; Testa B; Marrel C; Cooper DR; Jenner P; Marsden CD
Drug Des Deliv; 1987 Dec; 2(2):135-43. PubMed ID: 3509346
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and in vitro chemical and enzymatic stability of glycosyl 3'-azido-3'-deoxythymidine derivatives as potential anti-HIV agents.
Bonina F; Puglia C; Rimoli MG; Avallone L; Abignente E; Boatto G; Nieddu M; Meli R; Amorena M; de Caprariis P
Eur J Pharm Sci; 2002 Aug; 16(3):167-74. PubMed ID: 12128171
[TBL] [Abstract][Full Text] [Related]
16. L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease.
Cooper DR; Marrel C; van de Waterbeemd H; Testa B; Jenner P; Marsden CD
J Pharm Pharmacol; 1987 Aug; 39(8):627-35. PubMed ID: 2888854
[TBL] [Abstract][Full Text] [Related]
17. Designing prodrugs for the treatment of Parkinson's disease.
Sozio P; Cerasa LS; Abbadessa A; Di Stefano A
Expert Opin Drug Discov; 2012 May; 7(5):385-406. PubMed ID: 22494466
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs.
Kao HD; Traboulsi A; Itoh S; Dittert L; Hussain A
Pharm Res; 2000 Aug; 17(8):978-84. PubMed ID: 11028945
[TBL] [Abstract][Full Text] [Related]
19. The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
Hoon M; Petzer JP; Viljoen F; Petzer A
Molecules; 2017 Nov; 22(12):. PubMed ID: 29186917
[TBL] [Abstract][Full Text] [Related]
20. Esters of L-dopa: structure-hydrolysis relationships and ability to induce circling behaviour in an experimental model of hemiparkinsonism.
Brunner-Guenat M; Carrupt PA; Lisa G; Testa B; Rose S; Thomas K; Jenner P; Ventura P
J Pharm Pharmacol; 1995 Oct; 47(10):861-9. PubMed ID: 8583357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
